Exelixis, Inc. (EXEL) Analysts See $0.12 EPS

April 20, 2018 - By Linda Rogers

Exelixis, Inc. (NASDAQ:EXEL) LogoInvestors sentiment increased to 1.57 in 2017 Q4. Its up 0.34, from 1.23 in 2017Q3. It increased, as 26 investors sold Exelixis, Inc. shares while 66 reduced holdings. 59 funds opened positions while 85 raised stakes. 232.85 million shares or 1.85% less from 237.25 million shares in 2017Q3 were reported.
Sheets Smith Wealth Mgmt has invested 0.07% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL). Citigroup Inc owns 139,051 shares for 0% of their portfolio. Gam Ag has 0.05% invested in Exelixis, Inc. (NASDAQ:EXEL) for 51,000 shares. American Century has 0.04% invested in Exelixis, Inc. (NASDAQ:EXEL). Fuller And Thaler Asset Mgmt Inc has invested 0% in Exelixis, Inc. (NASDAQ:EXEL). Moreover, Cwm Limited Liability Company has 0% invested in Exelixis, Inc. (NASDAQ:EXEL) for 168 shares. Millennium Lc, a New York-based fund reported 1.16M shares. World Asset Management has 12,894 shares for 0.01% of their portfolio. Toronto Dominion Savings Bank accumulated 690 shares or 0% of the stock. Wellington Mgmt Llp invested in 214,403 shares. Schwab Charles Invest Mgmt owns 1.02M shares. 38,804 were accumulated by Sei Invests. Trexquant Inv Ltd Partnership, Connecticut-based fund reported 69,390 shares. D E Shaw & Inc, a New York-based fund reported 1.06M shares. Royal State Bank Of Canada invested in 0% or 325,609 shares.

Since January 8, 2018, it had 0 insider buys, and 9 selling transactions for $6.02 million activity. Another trade for 30,000 shares valued at $717,300 was made by WILLSEY LANCE on Friday, March 2. PAPADOPOULOS STELIOS had sold 15,000 shares worth $360,750. The insider Garber Alan M sold $454,515. MORRISSEY MICHAEL had sold 90,000 shares worth $1.87 million on Wednesday, April 11. The insider MARCHESI VINCENT T sold $370,950. POSTE GEORGE sold $393,900 worth of stock or 15,000 shares.

Analysts expect Exelixis, Inc. (NASDAQ:EXEL) to report $0.12 EPS on May, 2 after the close.They anticipate $0.07 EPS change or 140.00 % from last quarter’s $0.05 EPS. EXEL’s profit would be $35.60 million giving it 43.48 P/E if the $0.12 EPS is correct. After having $0.12 EPS previously, Exelixis, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 1.04% or $0.22 during the last trading session, reaching $20.87. About 1.78 million shares traded. Exelixis, Inc. (NASDAQ:EXEL) has risen 5.01% since April 21, 2017 and is uptrending. It has underperformed by 6.54% the S&P500.

Exelixis, Inc. (NASDAQ:EXEL) Ratings Coverage

Among 5 analysts covering Exelixis (NASDAQ:EXEL), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Exelixis had 7 analyst reports since December 19, 2017 according to SRatingsIntel. As per Tuesday, January 16, the company rating was maintained by RBC Capital Markets. The firm has “Buy” rating by SunTrust given on Tuesday, December 19. The stock has “Buy” rating by SunTrust on Monday, January 22. As per Tuesday, February 27, the company rating was maintained by RBC Capital Markets. Piper Jaffray maintained Exelixis, Inc. (NASDAQ:EXEL) on Thursday, January 4 with “Buy” rating. The firm has “Outperform” rating given on Tuesday, February 27 by Oppenheimer. The stock of Exelixis, Inc. (NASDAQ:EXEL) has “Hold” rating given on Tuesday, February 27 by Stifel Nicolaus.

Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company has market cap of $6.19 billion. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. It has a 42.33 P/E ratio. The Company’s CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program.

Exelixis, Inc. (NASDAQ:EXEL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: